Itovebi, combined with Ibrance and Faslodex, is approved for specific advanced breast cancer cases with PIK3CA mutations. The INAVO120 trial showed Itovebi significantly improved progression-free ...
The developers of OpenFold3 have released an early version of the tool, which they hope will one day perform on par with DeepMind’s protein-structure model.
In 2020, news headlines repeated John Moult’s words at the end of a stunning competition: Artificial intelligence had “solved” a long-standing grand challenge in biology, protein structure prediction.
A three-decade-old competition that has spawned three Nobel laureates is becoming victim to the chaos at the National Institutes of Health. The Community Wide Experiment on the Critical Assessment of ...
PI3Kα inhibitors are approved to treat certain cancers with PIK3CA mutations, but resistance often develops during treatment. Researchers have now identified additional cancer mutations that arise to ...
OnKure Therapeutics, Inc. (NASDAQ:OKUR) is gearing up for a major event in Q4 of 2024, which is that it intends to release data from its phase 1 PIKture-01 study using OKI-219 for the treatment of ...
Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky. Kalinsky is a professor and director in the Division ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback